曲妥珠单抗联合吉西他滨或卡培他滨一线治疗HER-2阳性晚期乳腺癌的临床研究

Abstract
Figure/Table
References (16)
Related Citation (7)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore clinical effect of Trastuzumab combined with Gemcitabine or Capecitabine in the firstline treatment of HER-2 positive advanced breast cancer.Methods65 cases clinical data of HER-2 positive advanced breast cancer patients in our hospital from August 2012 to August 2016 were analyzed,which waere divided into the Herceptin combined with GEM group(30 cases)and the Herceptin combined with capecitabine group(35 cases)by different treatment method.The clinical efficacy and adverse reactions were observed in the two groups.ResultsThere was no significant difference between the two groups in the total remission rate of different metastatic sites (P＞0.05).There was no significant difference between the two groups in the incidence rate of adverse reactions,such as alopecia, leukopenia,thrombocytopenia,lower hemoglobin,gastrointestinal reaction,liver dysfunction,renal dysfunction,hand and foot syndrome and diarrhea (P＞0.05).ConclusionThe remission rate of Trastuzumab combined with Gemcitabine or Capecitabine in the first-line treatment of HER-2 positive advanced breast cancer is higher,adverse reactions can be tolerated,it is worthy of clinical promotion and application.

Key words： Trastuzumab Gemcitabine Capecitabine HER-2 positive Advanced breast cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Jiang-tao
	WANG Wei

Cite this article:

HE Jiang-tao,WANG Wei. Clinicalresearch ofTrastuzumab combined with Gemcitabineor Capecitabine in the first-line treatment of HER-2 positive advanced breast cancer[J]. 中国当代医药, 2017, 24(13): 97-99.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I13/97

[1]	吴静娜，李亮，黄喜文，等.复发转移三阴性乳腺癌卡培他滨维持治疗的临床观察[J].安徽医药，2016，20（6）：1181-1184.
[2]	Huang H，Jiang Z，Wang T，et al.Single-agentcapecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer[J].Anti Cancer Drugs，2012，23（7）：718-723.
[3]	罗海涛，邹静荷，古伟光，等.卡培他滨维持治疗对联合化疗有效的复发转移三阴乳腺癌的临床观察[J].重庆医学，2015，44（24）：3357-3359.
[4]	Karachaliou N，Ziras N，Syrigos K，et al.A muhicenter phase Ⅱ trial of docetaxel and capecitabine as salvage treatment in anthracy cline and taxane pretreated patients with metastatic breast cancer[J].Cancer Chemother Pharmacol，2012，70（1）：169-176.
[5]	陈二洪，梁建权，宋小宁.低剂量多西他赛与卡培他滨联用治疗复发转移乳腺癌的临床疗效[J].海峡药学，2016，28（8）：146-147.
[6]	Martin M，Makhson A，Gligorov J，et al.PhaseⅡ study of bevaci-zumab in combination with trastuzumab and capecitabine as first line treatment for HER-2-positive locally recurrent or metastatic breast cancer[J].Oncologist，2012，17 （4）：469-475.
[7]	王英哲，司文，令狐锐霞，等.卡培他滨联合吉西他滨或长春瑞滨治疗复发转移性乳腺癌的疗效观察[J].解放军医学院学报，2015，36（11）：1085-1088.
[8]	Tan WW，Allred JB，Salim M，et al.PhaseⅡ interventional study（N0337）ofcapecitabineincombinationwithvinorelbine and tras tuzumab for first-or second-line treatment of HER2-positivemetastaticbreastcancer：anorthcentralcancertreatment group trial[J].Clin Breast Cancer，2012，12（2）：81-86.
[9]	李瑞卿，张元梅，王书山，等.卡培他滨长期维持治疗三阴性乳腺癌1例[J].临床肿瘤学杂志，2016，21（5）：474-475.
[10]	Kamal AH，Camacho F，Anderson R，et al.Similarsurvival with single agent capecitabine or taxane in first-linetherapy for metastatic breast cancer[J].Breast Cancer Res Treat，2012，134（1）：371-378.
[11]	戚巧玲.吉西他滨联合卡培他滨方案治疗晚期乳腺癌临床观察[J].现代中西医结合杂志，2016，25（30）：3370-3372.
[12]	Stockler MR，Harvey VJ，Francis PA，et al.Capecitabine versus classical cyclophosphamide，methotrexate，and fluorouracil as first line chemotherapy for advanced breast cancer[J].J Clin Oncol，2011，29（34）：4498-4504.
[13]	吕红琼，谢玲，倪明立，等.吉西他滨联合卡培他滨治疗复发转移乳腺癌的疗效观察[J].中国癌症防治杂志，2016，8（4）：249-251.
[14]	Huang H，Jiang Z，Wang T，et al.Single-agent capecitabine main-tenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer[J].Anti-cancer Drugs，2012，23（7）：718-723.
[15]	应文敏，郑兰飞，胡可，等.卡培他滨联合多西他赛治疗乳腺癌脑转移的效果观察[J].中国现代医生，2016，54（31）：84-86.
[16]	张妮，周晓明.曲妥珠单抗联合阿霉素脂质体治疗HER-2过度表达乳腺癌的临床疗效分析[J].中国医院药学杂志，2015，35（23）：2126-2128.